Critical care medicine
-
Critical care medicine · Dec 2024
Sex Disparity in Extracorporeal Membrane Oxygenation Clinical Trial Enrollment.
Multiple studies have shown that extracorporeal membrane oxygenation (ECMO) is used clinically more often in men than women. Because clinical trials provide the basis for identifying patients who are likely to benefit from medical therapies, we hypothesized that sex-based imbalances in ECMO trial enrollment may both reflect and perpetuate these observed disparities. Our objective was to determine whether sex-based enrollment imbalances exist within the published ECMO clinical trial literature. ⋯ Substantial sex-based disparity exists in published ECMO clinical trials. Underrepresentation of women relative to disease prevalence is most significant among trials utilizing venoarterial ECMO for cardiogenic shock and ECPR for cardiac arrest, limiting the applicability of findings from these trials for women.
-
Critical care medicine · Dec 2024
Mortality Risks and Causes in Previous Carbon Monoxide Poisoning: A Nationwide Population-Based Cohort Study.
Carbon monoxide (CO) poisoning can cause brain, heart, and kidney injuries. We aimed to determine the association of risks of all-cause and cause-specific mortality in patients with previous CO poisoning. ⋯ Patients with CO poisoning exhibited a heightened risk of all-cause mortality compared with the matched controls. Additionally, the cause-specific mortality risk differed between the groups.
-
Critical care medicine · Dec 2024
Racial Equity in Family Approach for Patients Medically Suitable for Deceased Organ Donation.
To conduct a contemporary analysis of the association between family approach of medically suitable potential organ donors and race/ethnicity. ⋯ Findings indicate racial equity in OPO family approach rates among patients who were medically suitable for organ donation.
-
Critical care medicine · Dec 2024
ReviewAngiotensin-II and Thromboembolic Events: A Systematic Review.
To evaluate and synthesize the existing evidence for the association of angiotensin-II with thromboembolic events. ⋯ Published evidence does not currently support or refute an association between angiotensin-II and an increased risk of venous or arterial thromboembolic events. Given the limited quality of available data, future studies should explicitly define diagnostic and reporting criteria for such events.